Statin Selection for Primary Prevention in Adults with Moderate Hypercholesterolemia

Introduction to Statin Therapy

The American College of Cardiology and American Heart Association recommend starting with moderate-intensity statin therapy using atorvastatin 10-20 mg or rosuvastatin 5-10 mg daily for primary prevention in adults with moderate hypercholesterolemia, with the decision to initiate therapy based on the 10-year ASCVD risk calculation 1

The 10-year ASCVD risk should be calculated using the Pooled Cohort Equations risk calculator for adults aged 40-75 years with LDL-C 70-189 mg/dL without diabetes or established cardiovascular disease, as recommended by the ACC/AHA guidelines 2, 1
If the 10-year ASCVD risk is ≥7.5%, initiate moderate-to-high intensity statin therapy with shared decision-making 1
If the 10-year ASCVD risk is 5% to <7.5%, engage in patient-clinician discussion regarding statin initiation, considering risk-enhancing factors 1
If the 10-year ASCVD risk is <5%, statin therapy is generally not recommended, and lifestyle modifications should be prioritized 2

For adults with moderate hypercholesterolemia, the American College of Cardiology recommends initiating moderate-intensity statin therapy with atorvastatin 10-20 mg daily, which provides 30-40% LDL-C reduction 3, 4
An alternative option is rosuvastatin 5-10 mg daily, which provides 30-49% LDL-C reduction, as recommended by the American College of Cardiology 3, 4

The American College of Cardiology recommends a dietary pattern emphasizing vegetables, fruits, whole grains, legumes, low-fat protein sources, and nontropical vegetable oils, while limiting sweets, sugar-sweetened beverages, and red meats 3
Adults with moderate hypercholesterolemia should engage in aerobic physical activity 3-4 sessions per week, lasting 40 minutes per session on average, involving moderate-to-vigorous intensity, as recommended by the American College of Cardiology 3
Caloric intake should be adjusted to avoid weight gain or promote weight loss if overweight/obese, according to the American College of Cardiology guidelines 3

The American College of Cardiology recommends reassessing fasting lipid panel at 4-12 weeks after initiating statin therapy to estimate efficacy, with an expected approximately 1% ASCVD risk reduction for every 1% LDL-C reduction 3
If LDL-C goal is not achieved and 10-year ASCVD risk warrants more aggressive therapy, the American College of Cardiology suggests increasing to high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) 3, 4

The American College of Cardiology and American Heart Association recommend not prescribing a statin without first calculating 10-year ASCVD risk, as this patient may not meet the threshold for statin therapy if their risk is <7.5% 2, 1
The American College of Cardiology advises against starting with low-intensity statins (simvastatin 10 mg, pravastatin 10-20 mg), as these provide <30% LDL-C reduction and are insufficient for primary prevention when statin therapy is indicated 3, 4
The American College of Cardiology recommends not using simvastatin 80 mg due to increased myopathy risk, including rhabdomyolysis 3, 4
The American College of Cardiology suggests not adding non-statin agents (ezetimibe, fibrates, PCSK9 inhibitors) at this stage, but rather maximizing evidence-based statin therapy first before considering combination therapy 3, 4